MI-EATON
16.11.2021 12:32:13 CET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has demonstrated cylinder deactivation (CDA) as an effective technology for meeting future global emissions requirements for diesel-engine powered commercial vehicles. To date, the technology has been evaluated with a close-coupled selective catalytic reduction (SCR) aftertreatment system with and without a 48-volt electric heater.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005234/en/
“Our CDA technology has proven it can help our customers meet increasingly strict emissions regulations for diesel engines,” said Christopher Mancuso, business unit director, Engine Air Management, Eaton’s Vehicle Group. “This comes at a time when many global manufacturers are determining what technologies they will leverage in next-generation vehicles to reduce harmful emissions.”
New emissions regulations spearheaded by the California Air Resources Board (CARB), U.S. Environmental Protection Agency (EPA) and European Commission (EC) are slated for adoption in coming years. These agencies, in concert with other national and international regulators, seek to significantly reduce greenhouse gas (GHG) emissions and harmful air pollutants produced primarily by heavy-duty trucks, vans and buses.
Rapid catalyst warm-up essential
Eaton partnered with the Southwest Research Institute (SwRI), one of the oldest and largest independent, nonprofit, applied research and development organizations in the U.S., to demonstrate the feasibility of its Vehicle Group’s technology. The findings demonstrate that using CDA and a close-coupled SCR catalyst reduced both nitrous oxide (NOx) and carbon dioxide (CO2 ) emissions with fuel consumption savings of up to 40% at idle.
Previous results utilizing CDA and a close-coupled SCR catalyst demonstrated compliance to forthcoming U.S. regulations for NOx and CO2 emissions for diesel commercial vehicles. Testing with the new low-load cycle (LLC) resulted in a 5% drop in CO2 while dramatically reducing NOx. The assessment was developed by CARB to replicate real-world urban tractor and vocational vehicle operations at low engine loads.
Eaton’s 2021 testing with SwRI showed further advancement, dropping NOx levels by 99.4% on the composite federal test procedure (FTP) and lowering the LLC NOx to well within current guidelines. Notably, using the same aftertreatment system with the addition of a 48-volt electric heater located upstream of the SCR further achieved a reduction in CO2 .
CDA technology can benefit vehicle manufacturers facing tightening emissions standards in Europe as well. The next set of requirements, known as Euro VII for heavy-duty trucks, is targeted for the second part of the decade. In the U.S., CARB is introducing more stringent regulations as soon as 2024, while the EPA has circled 2027 to begin applying stricter emissions limits on new-model heavy-duty vehicles. Collectively, these standards are designed to reduce tailpipe NOx emissions up to 90%, accelerating the need for global engine manufacturers to employ additional emissions-reduction strategies such as electric catalyst heating. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets . By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
